"El Confidencial": Ideeea Therapeutics announces AGAcell®: An allogeneic cell therapy program in preclinical development for alopecia.

Ideeea Therapeutics announces AGAcell®: an allogeneic cell therapy program in preclinical development for alopecia.

Ideeea Therapeutics closes €2.3 million seed round to advance the development of advanced therapy medicinal products with an open science and high clinical impact approach.

AGAcell® is a preclinical research program that explores the use of allogeneic mesenchymal stem cells for alopecia, aiming to evaluate its potential as a single-session clinical procedure.

Madrid, June 3, 2025 – Ideeea Therapeutics, a Spanish biotech start-up focused on advanced therapy medicinal products (ATMPs), announces AGAcell®, a preclinical program investigating the intradermal administration of a patented formulation of GMP-grade allogeneic mesenchymal stem cells combined with a bioactive molecule, as a novel therapeutic approach for androgenetic alopecia.

Ideeea Therapeutics has successfully closed a €2.3 million seed funding round backed by private investors and supported by the Centre for the Development of Industrial Technology (CDTI), within the framework of the Spanish Government’s Strategic Project for Economic Recovery and Transformation (PERTE) for Vanguard Health, financed by the European Union – Next Generation EU funds.

Androgenetic alopecia goes beyond aesthetic concerns. The progressive loss of hair removes the scalp’s natural protective barrier, leading to chronic exposure to ultraviolet radiation, which is associated with increased photoaging and a higher risk of certain skin carcinomas. Studies also highlight its negative impact on self-esteem and mental health. In this context, Ideeea Tx is evaluating AGAcell® as a potential therapy to restore the follicular microenvironment and promote hair regeneration through a minimally invasive, non-surgical procedure. The program is led by Dr. Eduardo López Bran, PhD, Principal Investigator and internationally renowned trichologist, who heads the Dermatology Department at Hospital Clínico San Carlos (Madrid).

Ideeea Therapeutics operates under an open innovation model through strategic partnerships with leading public and private hospitals and research centers, integrating the entire value chain and driving ATMP development from research to GMP-compliant manufacturing. In addition to AGAcell®, the company participates in external programs focused on immune system restoration and regenerative therapies, offering a scalable manufacturing infrastructure in line with current European regulatory standards.

The biotech start-up was founded by a team of experienced healthcare executives from FARMALIDER, a Spanish pharmaceutical company with a solid track record in the development of prescription medicines, OTC products, and value-added formulations in the international B2B market. The project is led by Marisa Berenguer, CEO of FARMALIDER, and José Ángel Sánchez, PhD, Director of Innovation at Ideeea Tx.